Eli Lilly and Co. stock has returned just 1 percent per year in the nine years since CEO Sidney Taurel took office. Meanwhile,
Taurel has taken home $44 million in pay and been given stock options valued at $114 million more. But most Lilly shareholders
aren’t raising a call for Taurel to hit the trail.
Pfizer Inc.’s new inhaled insulin product, Exubera, has stumbled out of the gate. That would appear to keep the door open
for Eli Lilly and Co., as well as for other companies racing to develop inhaled insulin. But Pfizer’s troubles might cause
doctors and patients to sour on all inhaled insulin products.
Eli Lilly and Co.’s loss in May of a patent-infringement lawsuit brought by Ariad Pharmaceuticals
Inc. went down as the 6th-largest such jury award last year, a Bloomberg analysis shows.
Eli Lilly and Co. is facing another round of litigation over its star seller, Zyprexa, as insurers and third-party payers
ask to be reimbursed for covering the antipsychotic drug.
Eli Lilly and Co. has picked an insurer it knows extremely well to cover future problems in the high-stakes world of product liability litigation–itself. The Indianapolis drugmaker opted for self-insurance after struggling to find coverage in what it terms a “very restrictive insurance market.”
The July 21 announcement by Lilly Endowment Inc. that it will reduce its holdings in Eli Lilly and Co. by $2 billion will have enormous repercussions. It’s meant to decrease volatility in the endowment’s assets, but it also erodes one of Lilly’s key antitakeover provisions.
